Adverse reactions to angiotensin-converting enzyme (ACE) inhibitors have been demonstrably more prevalent in African Americans compared to white Americans, and the risk of hemorrhagic complications in patients with intracranial hemorrhage treated with thrombolytics shows a similar relationship (Wright et al., 2005; Mehta et al., 2014). The gene discussed is ACE; the disease is intracranial hemorrhage.